Literature DB >> 18487999

MUC2 expression in primary mucinous and nonmucinous adenocarcinoma of the prostate: an analysis of 50 cases on radical prostatectomy.

Adeboye O Osunkoya1, N Volkan Adsay, Cynthia Cohen, Jonathan I Epstein, Stacey L Smith.   

Abstract

The expression of mucin (MUC2) in prostate cancer has not been well studied previously and may be of prognostic and pathobiologic significance. It is, however, well known that MUC2 expression in mucinous pancreatic and breast cancer represents an indolent pathway since these tumors have a significantly better outcome than their conventional counterparts. Twenty-five cases each of Gleason pattern 3 and 4 mucinous adenocarcinoma of the prostate defined by greater than 25% mucinous component and nonmucinous adenocarcinoma of the prostate were obtained from the surgical pathology files of the Johns Hopkins Hospital and Emory University Hospital. Immunohistochemical stains were performed for MUC2 on all 50 cases. Mean patient age was 60 years (range 44-72 years). MUC2 was expressed in all 25 cases (100%) of mucinous adenocarcinoma of the prostate, irrespective of the Gleason pattern. The nonmucinous component of these cases was negative for MUC2. In contrast, MUC2 expression was significantly lower in nonmucinous adenocarcinoma of the prostate, detected in only 6/25 cases as a focal finding, while 19/25 (76%) of nonmucinous adenocarcinoma of the prostate were completely negative for MUC2 (P<0.01). In six cases that showed focal positivity, MUC2 was expressed in areas with Gleason pattern 3 cancer with extensive mucinous fibroplasia (one case) and prominent intraluminal mucin (five cases). Other areas of these tumors were negative for MUC2. Mucinous adenocarcinoma of the prostate shows diffuse expression of MUC2, a known tumor suppressor, which is not present in either normal prostate or the majority of conventional adenocarcinomas of this organ. This indicates that mucinous adenocarcinoma of the prostate is indeed of the 'colloid type' akin to those in other exocrine organs. It is highly conceivable that this de novo expression of MUC2 has a role, not only in the mucinous differentiation of these tumors and their colloid pattern, but also in their relatively indolent behavior that has been recently elucidated.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487999     DOI: 10.1038/modpathol.2008.47

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma.

Authors:  Jae Eun Lee; Yoon Young Choi; Ji Yeong An; Ki Tae Kim; Su-Jin Shin; Jae-Ho Cheong
Journal:  Gastric Cancer       Date:  2022-05-09       Impact factor: 7.701

Review 2.  Functional Consequences of Differential O-glycosylation of MUC1, MUC4, and MUC16 (Downstream Effects on Signaling).

Authors:  Ryan L Hanson; Michael A Hollingsworth
Journal:  Biomolecules       Date:  2016-07-30

3.  Case Report: Prostate Adenocarcinoma With Mucinous Features of Normal-Level Serum PSA, Atypical Imaging, Biopsy-Negative, and Peculiar Urethrocystoscopic Manifestation.

Authors:  Yao Zhang; Hua Shen; Kai Liao; Weili Wu; Jiuming Li; Hongbo Yu; Hongfei Wu; Zengjun Wang
Journal:  Front Oncol       Date:  2020-12-23       Impact factor: 6.244

4.  Associations between the Expression of Mucins (MUC1, MUC2, MUC5AC, and MUC6) and Clinicopathologic Parameters of Human Breast Ductal Carcinomas.

Authors:  Sung-Im Do; Kyungeun Kim; Dong-Hoon Kim; Seoung Wan Chae; Yong Lai Park; Chan Heun Park; Jin Hee Sohn
Journal:  J Breast Cancer       Date:  2013-06-28       Impact factor: 3.588

5.  Comparing nodal versus bony metastatic spread using tumour phylogenies.

Authors:  Stefano Mangiola; Matthew K H Hong; Marek Cmero; Natalie Kurganovs; Andrew Ryan; Anthony J Costello; Niall M Corcoran; Geoff Macintyre; Christopher M Hovens
Journal:  Sci Rep       Date:  2016-09-22       Impact factor: 4.379

6.  Clinical Significance of Serum Membrane-Bound Mucin-2 Levels in Breast Cancer.

Authors:  Suleyman Bademler; Alisan Zirtiloglu; Murat Sari; Muhammed Zubeyr Ucuncu; Elif Bilgin Dogru; Senem Karabulut
Journal:  Biomolecules       Date:  2019-01-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.